+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen; By Indication (Diffuse Large B-Cell Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others); By Region: Segment Forecast, 2022 - 2029

  • ID: 5261980
  • Report
  • January 2022
  • Region: Global
  • 108 Pages
  • Polaris Market Research

FEATURED COMPANIES

  • Amgen Inc. (US)
  • Caribou Biosciences. (US)
  • Cellectis
  • Gilead Sciences.
  • Johnson & Johnson
  • Noile-Immune Biotech
The global CAR-T cell therapy market size is expected to reach USD 20,566.5 million by 2029 according to this new study. The report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2022-2029” provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market.



Chimeric antigen receptor CAR T therapy is a type of immunotherapy that modifies the immune system of a cancer patient to make it more effective at detecting and killing cancer cells. A protein is added to the surface of CAR T cells during the manufacturing process to assist them in acquiring this focus. This protein is called a chimeric antigen receptor, or CAR.

Diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, follicular lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukaemia (ALL) in pediatric and young adult patients up to the age of 25 are now treated using CAR T treatment. The US Food and Drug Administration has approved five CAR T medicines as of March 2021. (FDA).

CAR-T treatment is growing rapidly due to rising cancer cases. Additionally, technical advancements of diagnostic techniques in this industry, growing awareness among the people, and the increase in the geriatric population are contributing to and providing significant potential for industry growth.

North America is dominating the CAR-T market due to the number of life sciences companies focusing on the development and commercial manufacturing of CAR T-cells, as well as improvements in quality control systems in North America.

Some key players in the global industry include Amgen Inc (US), Bellicum Pharmaceuticals, Inc (US), Caribou Biosciences, Inc (US), Celgene Corporation, Bluebird Bio (US), Intellia Therapeutics, Johnson & Johnson, Cellectis, Celyad, Gilead Sciences, Inc, Merck KGaA, Nanjing Legend Biotechnology Co, Ltd, Noile-Immune Biotech, Novartis International AG, Pfizer Inc, Sangamo Therapeutics, Inc, Servier Laboratories.

The publisher has segmented the CAR-T cell therapy market report on the basis of target antigens, indications, and region:


CAR-T Cell Therapy, Target Antigens Outlook (Revenue, USD Million, 2017-2029)


  • CD19/CD22
  • BCMA (B-Cell Maturation Antigen)
  • Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY)

CAR-T Cell Therapy, Indication Outlook (Revenue, USD Million, 2017-2029)


  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Acute Lymphoblastic Leukemia (ALL)
  • Chronic Lymphocytic Leukemia (CLL)
  • Multiple Myeloma (MM)
  • Follicular Lymphoma (FL)
  • Others

CAR-T Cell Therapy Regional Outlook (Revenue, USD Million, 2017-2029)


  • North America
  • U.S
  • Canada
  • Europe
  • France
  • Germany
  • Switzerland
  • Asia Pacific
  • China
  • Japan
  • Rest of World
Frequently Asked Questions about the CAR-T Cell Therapy Market

What is the estimated value of the CAR-T Cell Therapy Market?

The CAR-T Cell Therapy Market was estimated to be valued at $1965.8 Million in 2022.

What is the growth rate of the CAR-T Cell Therapy Market?

The growth rate of the CAR-T Cell Therapy Market is 39.8%, with an estimated value of $20566.5 Million by 2029.

What is the forecasted size of the CAR-T Cell Therapy Market?

The CAR-T Cell Therapy Market is estimated to be worth $20566.5 Million by 2029.

Who are the key companies in the CAR-T Cell Therapy Market?

Key companies in the CAR-T Cell Therapy Market include Amgen Inc. (US), Bellicum Pharmaceuticals. (US), Bluebird Bio (US), Caribou Biosciences. (US), Celgene Corporation, Cellectis, Celyad, Gilead Sciences. and Johnson & Johnson.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc. (US)
  • Caribou Biosciences. (US)
  • Cellectis
  • Gilead Sciences.
  • Johnson & Johnson
  • Noile-Immune Biotech
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary
2.1. Market Highlights

3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources

4. CAR-T Cell Therapy Market Insights
4.1. CAR-T Cell Therapy Market - Industry Snapshot
4.2. CAR-T Cell Therapy Market Dynamics
4.2.1. Drivers and Opportunities
4.2.2. Restraints and Challenges
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Value Chain Analysis
4.6. CAR-T Cell Therapy Industry trends
4.7. COVID-19 Impact Analysis

5. Global CAR-T Cell Therapy Market, by Target Antigen
5.1. Key Findings
5.2. Introduction
5.2.1. Global CAR-T Cell Therapy, by Target Antigen, 2017 - 2029 (USD Million)
5.3. CD19/CD22
5.3.1. Global CAR-T Cell Therapy Market, by CD19/CD22, by Region, 2017 - 2029 (USD Million)
5.4. BCMA (B-Cell Maturation Antigen)
5.4.1. Global CAR-T Cell Therapy Market, by BCMA (B-Cell Maturation Antigen), by Region, 2017 - 2029 (USD Million)
5.5. Others
5.5.1. Global CAR-T Cell Therapy Market, by Others, by Region, 2017 - 2029 (USD Million)

6. Global CAR-T Cell Therapy Market, by Indication
6.1. Key Findings
6.2. Introduction
6.2.1. Global CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
6.3. Diffuse Large B-Cell Lymphoma (DLBCL)
6.3.1. Global CAR-T Cell Therapy Market, by Diffuse Large B-Cell Lymphoma (DLBCL), by Region, 2017 - 2029 (USD Million)
6.4. Acute Lymphoblastic Leukemia (ALL)
6.4.1. Global CAR-T Cell Therapy Market, by Acute Lymphoblastic Leukemia (ALL), by Region, 2017 - 2029 (USD Million)
6.5. Chronic Lymphocytic Leukemia (CLL)
6.5.1. Global CAR-T Cell Therapy Market, by Chronic Lymphocytic Leukemia (CLL), by Region, 2017 - 2029 (USD Million)
6.6. Multiple Myeloma (MM)
6.6.1. Global CAR-T Cell Therapy Market, by Multiple Myeloma (MM), by Region, 2017 - 2029 (USD Million)
6.7. Follicular Lymphoma (FL)
6.7.1. Global CAR-T Cell Therapy Market, by Follicular Lymphoma (FL), by Region, 2017 - 2029 (USD Million)
6.8. Others
6.8.1. Global CAR-T Cell Therapy Market, by Others, by Region, 2017 - 2029 (USD Million)

7. Global CAR-T Cell Therapy Market, by Geography
7.1. Key findings
7.2. Introduction
7.2.1. CAR-T Cell Therapy Market Assessment, By Geography, 2017 - 2029 (USD Million)
7.3. CAR-T Cell Therapy Market - North America
7.3.1. North America: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
7.3.2. North America: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
7.3.3. CAR-T Cell Therapy Market - U.S.
7.3.3.1. U.S.: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
7.3.3.2. U.S.: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
7.3.4. CAR-T Cell Therapy Market - Canada
7.3.4.1. Canada: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
7.3.4.2. Canada: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
7.4. CAR-T Cell Therapy Market - Europe
7.4.1. Europe: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
7.4.2. Europe: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
7.4.3. CAR-T Cell Therapy Market - France
7.4.3.1. France: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
7.4.3.2. France: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
7.4.4. CAR-T Cell Therapy Market - Germany
7.4.4.1. Germany: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
7.4.4.2. Germany: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
7.4.5. CAR-T Cell Therapy Market - Switzerland
7.4.5.1. Switzerland: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
7.4.5.2. Switzerland: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
7.5. CAR-T Cell Therapy Market - Asia Pacific
7.5.1. Asia Pacific: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
7.5.2. Asia Pacific: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
7.5.3. CAR-T Cell Therapy Market - China
7.5.3.1. China: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
7.5.3.2. China: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
7.5.4. CAR-T Cell Therapy Market - Japan
7.5.4.1. Japan: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
7.5.4.2. Japan: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
7.6. CAR-T Cell Therapy Market - Rest of World
7.6.1. Rest of World: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
7.6.2. Rest of World: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)

8. Competitive Landscape
8.1. Expansion and Acquisition Analysis
8.1.1. Expansion
8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles
9.1. Amgen Inc. (US)
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Recent Development
9.2. Bellicum Pharmaceuticals Inc. (US)
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Product Benchmarking
9.2.4. Recent Development
9.3. Bluebird Bio (US)
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Product Benchmarking
9.3.4. Recent Development
9.4. Caribou Biosciences, Inc. (US)
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Benchmarking
9.4.4. Recent Development
9.5. Celgene Corporation
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Product Benchmarking
9.5.4. Recent Development
9.6. Cellectis
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Product Benchmarking
9.6.4. Recent Development
9.7. Celyad
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Product Benchmarking
9.7.4. Recent Development
9.8. Gilead Sciences, Inc.
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Product Benchmarking
9.8.4. Recent Development
9.9. Intellia Therapeutics
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Product Benchmarking
9.9.4. Recent Development
9.10. Johnson & Johnson
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. Product Benchmarking
9.10.4. Recent Development
9.11. Merck KGaA
9.11.1. Company Overview
9.11.2. Financial Performance
9.11.3. Product Benchmarking
9.11.4. Recent Development
9.12. Nanjing Legend Biotechnology Co., Ltd
9.12.1. Company Overview
9.12.2. Financial Performance
9.12.3. Product Benchmarking
9.12.4. Recent Development
9.13. Noile-Immune Biotech
9.13.1. Company Overview
9.13.2. Financial Performance
9.13.3. Product Benchmarking
9.13.4. Recent Development
9.14. Novartis International AG
9.14.1. Company Overview
9.14.2. Financial Performance
9.14.3. Product Benchmarking
9.14.4. Recent Development
9.15. Pfizer Inc.
9.15.1. Company Overview
9.15.2. Financial Performance
9.15.3. Product Benchmarking
9.15.4. Recent Development
9.16. Sangamo Therapeutics, Inc.
9.16.1. Company Overview
9.16.2. Financial Performance
9.16.3. Product Benchmarking
9.16.4. Recent Development
9.17. Servier Laboratories
9.17.1. Company Overview
9.17.2. Financial Performance
9.17.3. Product Benchmarking
9.17.4. Recent Development

List of Tables
Table 1 Global CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
Table 2 Global CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
Table 3 CAR-T Cell Therapy Market Assessment, By Geography, 2017 - 2029 (USD Million)
Table 4 North America: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
Table 5 North America: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
Table 6 U.S.: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
Table 7 U.S.: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
Table 8 Canada: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
Table 9 Canada: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
Table 10 Europe: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
Table 11 Europe: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
Table 12 Germany: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
Table 13 Germany: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
Table 14 France: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
Table 15 France: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
Table 16 Switzerland: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
Table 17 Switzerland: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
Table 18 Asia Pacific: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
Table 19 Asia Pacific: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
Table 20 China: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
Table 21 China: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
Table 22 Japan: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
Table 23 Japan: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
Table 24 Rest of World: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
Table 25 Rest of World: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)

List of Figures
Figure 1 Global CAR-T Cell Therapy Market, 2017 - 2029 (USD Million)
Figure 2 Integrated Ecosystem
Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
Figure 4 Market by Geography
Figure 5 Porter’s Five Forces
Figure 6 Market by Indication
Figure 7 Global CAR-T Cell Therapy Market, by Indication, 2021 & 2029 (USD Million)
Figure 8 Market by Target Antigen
Figure 9 Global CAR-T Cell Therapy Market, by Target Antigen, 2021 & 2029 (USD Million)
Figure 10 CAR-T Cell Therapy Market Assessment, By Geography, 2017 - 2029 (USD Million)
Figure 11 Strategic Analysis – CAR-T Cell Therapy Market
Note: Product cover images may vary from those shown
  • Amgen Inc. (US)
  • Bellicum Pharmaceuticals. (US)
  • Bluebird Bio (US)
  • Caribou Biosciences. (US)
  • Celgene Corporation
  • Cellectis
  • Celyad
  • Gilead Sciences.
  • Intellia Therapeutics
  • Johnson & Johnson
  • Mereck KGaA
  • Nanjing Legend Biotechnology Co. Ltd.
  • Noile-Immune Biotech
  • Novartis International AG
  • Pfizer Inc.
  • Sangamo Therapeutics.
  • Servier Laboratories.
Note: Product cover images may vary from those shown